Incyte Corp (INCY)

$123.47 -0.03 (-0.02%)
Market Cap 25.03B
Revenue (ttm) 5.14B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 15.13
Forward PE 45.60
Profit Margin 25.03%
Debt to Equity Ratio 0.00
Volume 1,191,400
Avg Vol 1,935,000
Day's Range N/A - N/A
Shares Out 202.70M
Stochastic %K 86%
Beta 0.76
Analysts Sell
Price Target $127.09

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 498 6700
Address:
1801 Augustine Cut-Off, Wilmington, United States
WAJeff
WAJeff Aug. 18 at 7:22 PM
$INCY Should have owned this one too
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:59 PM
$PSX $WCC $INCY $GMAB $GH easy
0 · Reply
Doozio
Doozio Aug. 16 at 4:19 PM
how many tight weekly closes now? Let’s get an $INCY wincy shakeout vs the 50d and a turnaround Tuesday ENTA 🐒🍌🧠⏰♾️
0 · Reply
Nomorelies
Nomorelies Aug. 10 at 9:04 PM
$INCY Happily
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Aug. 10 at 6:17 PM
$INCY $ABCL $NKTR $UTHR $EXEL when I’m not being beartard and pissed sometimes be sweet w it
0 · Reply
ortega1963
ortega1963 Aug. 8 at 3:18 PM
$INCY Watching this Stock
0 · Reply
Nomorelies
Nomorelies Aug. 7 at 12:11 AM
$INCY WOW! Now that’s a turn around!!
1 · Reply
Nomorelies
Nomorelies Aug. 5 at 1:25 PM
$INCY
0 · Reply
Estimize
Estimize Aug. 5 at 11:03 AM
Wall St is expecting 1.97 EPS for $INCY Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/incy?chart=historical&metric_name=eps&utm_co
0 · Reply
Nomorelies
Nomorelies Aug. 4 at 7:45 PM
$INCY is running on all cylinders. https://stockstotrade.com/news/incyte-corporation-incy-news-2026_07_28/
0 · Reply
Latest News on INCY
Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness

Aug 17, 2026, 11:14 AM EDT - 1 day ago

Global Vitiligo Foundation Applauds Incyte's “Moments of Clarity” Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness

INCY

Incyte price target raised to $130 from $110 at Piper Sandler

2026-08-17T11:05:24.000Z - 2 days ago

Incyte price target raised to $130 from $110 at Piper Sandler

INCY

Incyte price target raised to $104 from $99 at Bernstein

2026-08-17T07:56:32.000Z - 2 days ago

Incyte price target raised to $104 from $99 at Bernstein

INCY

Incyte Sales Growth Drives Share Price Gains

Aug 12, 2026, 12:38 PM EDT - 6 days ago

Incyte Sales Growth Drives Share Price Gains

INCY

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2026, 4:30 PM EDT - 11 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY

Incyte price target raised to $137 from $121 at Mizuho

2026-08-04T12:17:31.000Z - 15 days ago

Incyte price target raised to $137 from $121 at Mizuho

INCY

Incyte price target raised to $155 from $131 at Leerink

2026-08-03T10:15:31.000Z - 16 days ago

Incyte price target raised to $155 from $131 at Leerink

INCY

Incyte price target raised to $120 from $110 at JPMorgan

2026-07-30T13:26:50.000Z - 19 days ago

Incyte price target raised to $120 from $110 at JPMorgan

INCY

Incyte price target raised to $109 from $99 at RBC Capital

2026-07-29T13:56:24.000Z - 20 days ago

Incyte price target raised to $109 from $99 at RBC Capital

INCY

Incyte price target raised to $130 from $112 at BMO Capital

2026-07-29T12:12:11.000Z - 21 days ago

Incyte price target raised to $130 from $112 at BMO Capital

INCY

Incyte price target raised to $150 from $136 at Guggenheim

2026-07-29T12:11:34.000Z - 21 days ago

Incyte price target raised to $150 from $136 at Guggenheim

INCY

Incyte price target raised to $119 from $104 at Morgan Stanley

2026-07-29T11:10:26.000Z - 21 days ago

Incyte price target raised to $119 from $104 at Morgan Stanley

INCY

Incyte says EC approves Opzelura cream for treatment of AD

2026-07-29T10:20:55.000Z - 21 days ago

Incyte says EC approves Opzelura cream for treatment of AD

INCY

Incyte price target raised to $140 from $136 at BofA

2026-07-29T10:20:20.000Z - 21 days ago

Incyte price target raised to $140 from $136 at BofA

INCY

Incyte price target raised to $150 from $140 at H.C. Wainwright

2026-07-29T10:00:24.000Z - 21 days ago

Incyte price target raised to $150 from $140 at H.C. Wainwright

INCY

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Jul 29, 2026, 6:00 AM EDT - 21 days ago

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

INCY

Incyte price target raised to $139 from $134 at Barclays

2026-07-29T09:25:39.000Z - 21 days ago

Incyte price target raised to $139 from $134 at Barclays

INCY

Incyte price target raised to $145 from $123 at Stifel

2026-07-28T17:50:27.000Z - 21 days ago

Incyte price target raised to $145 from $123 at Stifel

INCY

Incyte price target raised to $120 from $107 at Oppenheimer

2026-07-28T17:45:19.000Z - 21 days ago

Incyte price target raised to $120 from $107 at Oppenheimer

INCY

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

2026-07-28T14:45:41.000Z - 21 days ago

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

INCY PRLD

Incyte lifts annual revenue forecast after settlement with CMS

Jul 28, 2026, 9:00 AM EDT - 21 days ago

Incyte lifts annual revenue forecast after settlement with CMS

INCY

Incyte Earnings Call Transcript: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Incyte Earnings Call Transcript: Q2 2026

Incyte Earnings release: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Incyte Earnings release: Q2 2026

Incyte Slides: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Incyte Slides: Q2 2026

Incyte Quarterly report: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 22 days ago

Incyte Quarterly report: Q2 2026

Incyte reports Q2 EPS $3.09, consensus $2.15

2026-07-28T11:11:12.000Z - 22 days ago

Incyte reports Q2 EPS $3.09, consensus $2.15

INCY

Incyte raises FY26 revenue view to $5.13B-$5.26B from $4.77B-$4.94B

2026-07-28T11:10:30.000Z - 22 days ago

Incyte raises FY26 revenue view to $5.13B-$5.26B from $4.77B-$4.94B

INCY

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Jul 28, 2026, 7:00 AM EDT - 22 days ago

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

INCY

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Jul 20, 2026, 8:00 AM EDT - 4 weeks ago

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

HALO INCY

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Jul 17, 2026, 1:10 PM EDT - 4 weeks ago

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

INCY

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Jul 13, 2026, 4:00 AM EDT - 5 weeks ago

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

INCY

Incyte to Report Second Quarter Financial Results

Jul 8, 2026, 8:00 AM EDT - 6 weeks ago

Incyte to Report Second Quarter Financial Results

INCY

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Jul 6, 2026, 8:39 AM EDT - 6 weeks ago

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

INCY

Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion

Jul 3, 2026, 11:58 AM EDT - 6 weeks ago

Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion

INCY

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Jun 26, 2026, 7:30 AM EDT - 7 weeks ago

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

INCY

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Jun 19, 2026, 2:00 AM EDT - 2 months ago

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

INCY

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

Jun 14, 2026, 4:35 PM EDT - 2 months ago

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

INCY MIRM

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Jun 13, 2026, 11:15 AM EDT - 2 months ago

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

INCY

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Jun 13, 2026, 6:00 AM EDT - 2 months ago

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

INCY

Incyte Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 8:40 AM EDT - 2 months ago

Incyte Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Incyte Transcript: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Incyte Transcript: M&A announcement

Incyte Press release: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Incyte Press release: M&A announcement

Incyte Slides: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Incyte Slides: M&A announcement

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Jun 8, 2026, 7:34 AM EDT - 2 months ago

Incyte to Buy Vega Therapeutics For Up to $2 Billion

INCY

Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary

Jun 8, 2026, 7:07 AM EDT - 2 months ago

Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary

INCY

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Jun 8, 2026, 7:00 AM EDT - 2 months ago

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

INCY

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

Jun 7, 2026, 6:11 AM EDT - 2 months ago

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

INCY

Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate

May 30, 2026, 8:02 AM EDT - 2 months ago

Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate

INCY

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

May 30, 2026, 8:00 AM EDT - 2 months ago

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

INCY

Incyte Proxy statement: Proxy filing

May 27, 2026, 8:00 AM EDT - 3 months ago

Incyte Proxy statement: Proxy filing

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026, 8:00 AM EDT - 3 months ago

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

INCY

Inside Incyte's $120 Million AI For Drug Development Deal

May 20, 2026, 12:10 PM EDT - 3 months ago

Inside Incyte's $120 Million AI For Drug Development Deal

INCY

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

May 20, 2026, 8:00 AM EDT - 3 months ago

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

INCY

Incyte Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 10:30 AM EDT - 3 months ago

Incyte Transcript: RBC Capital Markets Global Healthcare Conference 2026

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

May 19, 2026, 8:00 AM EDT - 3 months ago

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

INCY

Incyte Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 4:40 PM EDT - 3 months ago

Incyte Transcript: Bank of America Global Healthcare Conference 2026

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

May 12, 2026, 9:30 AM EDT - 3 months ago

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

INCY

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

May 7, 2026, 8:50 AM EDT - 3 months ago

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

INCY

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

May 1, 2026, 5:28 PM EDT - 3 months ago

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

INCY

Incyte to Present at Upcoming Investor Conferences

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Incyte to Present at Upcoming Investor Conferences

INCY

Incyte beats first-quarter estimates on strong demand for cancer drugs

Apr 28, 2026, 10:01 AM EDT - 4 months ago

Incyte beats first-quarter estimates on strong demand for cancer drugs

INCY

Incyte Earnings Call Transcript: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Incyte Earnings Call Transcript: Q1 2026

Incyte Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Incyte Earnings release: Q1 2026

Incyte Slides: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Incyte Slides: Q1 2026

Incyte Quarterly report: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Incyte Quarterly report: Q1 2026

Incyte Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Incyte Proxy statement: Proxy filing

Incyte Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Incyte Proxy statement: Proxy filing

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

INCY

Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

INCY

Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 21, 2026, 10:00 AM EDT - 4 months ago

Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

INCY

Incyte to Report First Quarter Financial Results

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Incyte to Report First Quarter Financial Results

INCY

Incyte's skin disease drug shows long-term symptom relief in late-stage trials

Mar 28, 2026, 3:04 PM EDT - 5 months ago

Incyte's skin disease drug shows long-term symptom relief in late-stage trials

INCY

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 28, 2026, 3:00 PM EDT - 5 months ago

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

INCY

Incyte Announces Executive Leadership Appointments

Mar 25, 2026, 9:00 AM EDT - 5 months ago

Incyte Announces Executive Leadership Appointments

INCY

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 20, 2026, 10:00 AM EDT - 5 months ago

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

INCY

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

Mar 17, 2026, 7:30 AM EDT - 5 months ago

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

INCY

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

Mar 17, 2026, 7:30 AM EDT - 5 months ago

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

INCY

Incyte Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 8:30 AM EDT - 5 months ago

Incyte Transcript: Barclays 28th Annual Global Healthcare Conference

Incyte Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 9:20 AM EDT - 5 months ago

Incyte Transcript: Leerink Global Healthcare Conference 2026

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Mar 6, 2026, 4:42 PM EST - 5 months ago

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

INCY

Incyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 6 months ago

Incyte Transcript: TD Cowen 46th Annual Health Care Conference

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

Feb 27, 2026, 8:11 AM EST - 6 months ago

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

INCY LLY

Incyte weak 2026 revenue forecast heightens Jakafi patent concerns

Feb 10, 2026, 8:13 AM EST - 6 months ago

Incyte weak 2026 revenue forecast heightens Jakafi patent concerns

INCY

Incyte Earnings Call Transcript: Q4 2025

Feb 10, 2026, 8:00 AM EST - 6 months ago

Incyte Earnings Call Transcript: Q4 2025

Incyte Annual report: Q4 2025

Feb 10, 2026, 8:00 AM EST - 6 months ago

Incyte Annual report: Q4 2025

Incyte Earnings release: Q4 2025

Feb 10, 2026, 8:00 AM EST - 6 months ago

Incyte Earnings release: Q4 2025

Incyte Slides: Q4 2025

Feb 10, 2026, 8:00 AM EST - 6 months ago

Incyte Slides: Q4 2025

Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 10, 2026, 7:00 AM EST - 6 months ago

Incyte Reports Fourth Quarter and Full Year 2025 Financial Results

INCY

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Jan 30, 2026, 9:29 AM EST - 7 months ago

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

INCY

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

Jan 27, 2026, 8:00 AM EST - 7 months ago

Incyte to Report Fourth Quarter and Year-End 2025 Financial Results

INCY

Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity

Jan 13, 2026, 6:02 PM EST - 7 months ago

Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity

INCY

Incyte Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 7 months ago

Incyte Transcript: 44th Annual J.P. Morgan Healthcare Conference

Incyte Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 7 months ago

Incyte Slides: 44th Annual J.P. Morgan Healthcare Conference

Incyte's blood cancer therapy meets main goal in late-stage trial

Jan 5, 2026, 7:40 AM EST - 8 months ago

Incyte's blood cancer therapy meets main goal in late-stage trial

INCY

WAJeff
WAJeff Aug. 18 at 7:22 PM
$INCY Should have owned this one too
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 7:59 PM
$PSX $WCC $INCY $GMAB $GH easy
0 · Reply
Doozio
Doozio Aug. 16 at 4:19 PM
how many tight weekly closes now? Let’s get an $INCY wincy shakeout vs the 50d and a turnaround Tuesday ENTA 🐒🍌🧠⏰♾️
0 · Reply
Nomorelies
Nomorelies Aug. 10 at 9:04 PM
$INCY Happily
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Aug. 10 at 6:17 PM
$INCY $ABCL $NKTR $UTHR $EXEL when I’m not being beartard and pissed sometimes be sweet w it
0 · Reply
ortega1963
ortega1963 Aug. 8 at 3:18 PM
$INCY Watching this Stock
0 · Reply
Nomorelies
Nomorelies Aug. 7 at 12:11 AM
$INCY WOW! Now that’s a turn around!!
1 · Reply
Nomorelies
Nomorelies Aug. 5 at 1:25 PM
$INCY
0 · Reply
Estimize
Estimize Aug. 5 at 11:03 AM
Wall St is expecting 1.97 EPS for $INCY Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/incy?chart=historical&metric_name=eps&utm_co
0 · Reply
Nomorelies
Nomorelies Aug. 4 at 7:45 PM
$INCY is running on all cylinders. https://stockstotrade.com/news/incyte-corporation-incy-news-2026_07_28/
0 · Reply
Nomorelies
Nomorelies Aug. 4 at 7:10 PM
$INCY Nice upgrades!!
0 · Reply
jdlman
jdlman Aug. 4 at 4:36 PM
$INCY $BIIB ..shut up josh brown .. always says it after the fact
1 · Reply
IN0V8
IN0V8 Aug. 3 at 4:15 PM
$INCY Buy Leerink Partners raises target price to $155 from $131
0 · Reply
AlertsAndNews
AlertsAndNews Aug. 2 at 10:17 PM
$INCY New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS "In the pivotal Phase 3 inMIND clinical trial, patients with R/R FL receiving the Minjuvi combination regimen experienced a significant improvement in progression-free survival, with a 57% reduction in the risk of disease progression, relapse or death, compared with placebo plus lenalidomide and rituximab."
0 · Reply
2_logs_higher
2_logs_higher Jul. 30 at 3:45 PM
$INCY cnbc, buy on the pullback Final Trades: Meta, ServiceNow, eBay and Incyte - CNBC https://stocks.apple.com/ArzX7BQOiQGOj50s4bZ7EhA
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 29 at 5:22 PM
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod $INCY $VTI $VOO https://stocktwits.com/news/equity/markets/incyte-shares-retreat-after-best-day-in-a-year-despite-opzelura-eu-nod/cZNTReeRJT9
1 · Reply
NebulaNexus
NebulaNexus Jul. 29 at 4:38 PM
$INCY is trimming early-stage oncology programs to funnel capital into high-conviction clinical assets. A necessary pivot. The existential clock is ticking fast toward the Jakafi patent cliff. Pipeline headcount no longer impresses the tape. Execution speed and clinical validation are everything now. The core question: can upcoming candidates backfill the revenue gap before legacy cash flows dry up?
0 · Reply
Merlintrader
Merlintrader Jul. 29 at 10:39 AM
$INCY Incyte ($INCY) Stock Hub 2026: A Cash-Rich Jakafi Machine Racing Its Own 2028 Patent Cliff https://www.merlintrader.com/incyte-incy-stock-hub/
0 · Reply
Nomorelies
Nomorelies Jul. 29 at 3:27 AM
$INCY
0 · Reply
BioRich
BioRich Jul. 28 at 8:29 PM
$INCY Continues to look strong.
1 · Reply
notreload_ai
notreload_ai Jul. 28 at 5:05 PM
$PRLD stock rises after $INCY discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal. https://notreload.xyz/xy/prelude-shares-jump-as-incyte-drops-rival-jak2-drug/
1 · Reply
Nomorelies
Nomorelies Jul. 28 at 3:09 PM
$INCY Very
0 · Reply